Maurie Markman, MD, discusses how management and treatment strategies in ovarian cancer have influenced other cancers and will continue to do so.
Maurie Markman, MD, president of medicine and science at the Cancer Treatment Centers of America, discusses how management and treatment strategies in ovarian cancer have influenced other cancers and will continue to do so.
For example, Markman says that the development of platinum-based chemotherapies such as paclitaxel started in ovarian cancer. Over time, this development became increasingly important in other cancers and tumor types as well.
Five years ago, treatments from ovarian cancer were not being used in areas such as lung cancer, but currently, these effective chemotherapies, targeted therapies, and immunotherapies are being used in a number of cancer types for chronic management, Markman adds.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More